Article Text

Download PDFPDF

Conventional treatments for ankylosing spondylitis
Free
  1. M Dougados1,
  2. B Dijkmans2,
  3. M Khan3,
  4. W Maksymowych4,
  5. Sj van der Linden5,
  6. J Brandt6
  1. 1Department of Rheumatology, René Descartes University, Hôpital Cochin, Paris, France
  2. 2Department of Rheumatology, VU University Medical Centre, Amsterdam, The Netherlands
  3. 3Case Western Reserve University, Cleveland, Ohio, USA
  4. 4Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada
  5. 5Department of Medicine, Division of Rheumatology, University Hospital Maastricht, Maastricht, The Netherlands
  6. 6Department of Gastroenterology and Rheumatology, UKBF, Free University, Berlin, Germany
  1. Correspondence to:
    Dr M Dougados, Clinique de Rhumatologie, Hôpital Cochin, 27 rue du Faubourg Saint Jacques, F-75014 Paris, France;
    maxime.dougados{at}cch.ap-hop-paris.fr

Abstract

Management of ankylosing spondylitis (AS) is challenged by the progressive nature of the disease. To date, no intervention is available that alters the underlying mechanism of inflammation in AS. Currently available conventional treatments are palliative at best, and often fail to control symptoms in the long term. Current drug treatment may perhaps induce a spurious state of “disease remission,” which is merely a low level of disease activity. Non-steroidal anti-inflammatory drugs are first line treatment, but over time, the disease often becomes refractory to these agents. Disease modifying antirheumatic drugs are second line treatment and may offer some clinical benefit. However, conclusive evidence of the efficacy of these drugs from large placebo controlled trials is lacking. Additionally, these drugs can cause treatment-limiting adverse effects. Intra-articular corticosteroid injection guided by arthrography, computed tomography, or magnetic resonance imaging is an effective means of reducing inflammatory back pain, but controlled studies are lacking. A controlled study has confirmed moderate but significant efficacy of intravenous bisphosphonate (pamidronate) treatment in patients with AS; further evaluation of bisphosphonate treatment is warranted. Physical therapy and exercise are necessary adjuncts to pharmacotherapy; however, the paucity of controlled data makes it difficult to identify the best way to administer these interventions. Surgical intervention may be required to support severe structural damage. Thus, for patients with AS, the future of successful treatment lies in the development of pharmacological agents capable of both altering the disease course through intervention at sites of disease pathogenesis, and controlling symptoms.

  • ankylosing spondylitis
  • corticosteroid
  • disease modifying antirheumatic drugs
  • non-steroidal anti-inflammatory drugs
  • AS, ankylosing spondylitis
  • 5-ASA, 5-acetylsalicylic acid
  • ASAS, Assessments in Ankylosing Spondylitis (Working Group)
  • BASDAI, Bath AS Disease Activity Index
  • BASFI, Bath AS Functional Index
  • BASGI, Bath AS Global Index
  • BASMI, Bath AS Metrology Index
  • COX, cyclo-oxygenase
  • CRP, C reactive protein
  • CT, computed tomography
  • DMARD, disease modifying antirheumatic drug
  • ESR, erythrocyte sedimentation rate
  • IV, intravenous
  • MES, mesalazine
  • MRI, magnetic resonance imaging
  • NSAID, non-steroidal anti-inflammatory drug
  • RA, rheumatoid arthritis
  • SP, sulfapyridine
  • SpA, spondyloarthropathy
  • SSZ, sulfasalazine
  • THA, total hip arthroplasty
  • VAS, visual analogue scale
View Full Text

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.